|
Market Closed -
Nasdaq Stockholm
15:30:00 30/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 2.090 SEK | -1.42% |
|
+8.40% | +6.09% |
| 10-27 | Irlab Therapeutics Set to Obtain US Patent for Parkinson's Disease Drug Candidate | MT |
| 10-27 | Irlab receives positive patent notice in the US for IRL1117 | FW |
Company Valuation: IRLAB Therapeutics AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,277 | 1,987 | 389 | 557.6 | 167.3 | 310.8 | - |
| Change | - | -12.75% | -80.42% | 43.33% | -69.99% | 85.75% | - |
| Enterprise Value (EV) | 1,875 | 1,734 | 277.7 | 494.2 | 167.3 | 310.8 | 310.8 |
| Change | - | -7.53% | -83.98% | 77.96% | -66.14% | 85.75% | 0% |
| P/E | 44x | -17.5x | -2.19x | -6.72x | - | - | - |
| PBR | - | 6.83x | - | 17.1x | - | - | - |
| PEG | - | 0x | -0x | 0.1x | - | - | - |
| Capitalization / Revenue | 11x | 32.5x | 68.5x | 5.89x | 2.91x | 3.07x | 2.17x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 3.07x | 2.17x |
| EV / EBITDA | 0x | -0x | -0x | -0x | -0x | -10.9x | 8.05x |
| EV / EBIT | 0x | -0x | -0x | -0x | -0x | -9.9x | 8.98x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | 1 | -2.19 | -3.43 | -1.6 | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 207.8 | 61.14 | 5.678 | 94.63 | 57.46 | 101.2 | 143.2 |
| EBITDA 1 | 56.05 | -108.3 | -176.4 | -70.53 | -89.08 | -28.4 | 38.6 |
| EBIT 1 | 52.58 | -113.1 | -180.8 | -75.11 | -93.4 | -31.4 | 34.6 |
| Net income 1 | 51.78 | -113.4 | -177.8 | -83.13 | -110 | -36.1 | 34.6 |
| Net Debt | -401.9 | -252.8 | -111.3 | -63.38 | - | - | - |
| Reference price 2 | 44.000 | 38.300 | 7.500 | 10.750 | 1.970 | 2.090 | 2.090 |
| Nbr of stocks (in thousands) | 51,748 | 51,868 | 51,868 | 51,868 | 84,938 | 148,712 | - |
| Announcement Date | 2/23/22 A | 2/23/23 A | 2/7/24 A | 2/12/25 A | 2/25/26 A | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 31.64M | |
| 41.42x | 14.04x | 31.11x | 0.48% | 1,263B | |
| 39.99x | 6.71x | 18.89x | 1.95% | 658B | |
| 36.71x | 8.6x | 17.71x | 2.33% | 521B | |
| 21.74x | 5.27x | 13.12x | 2.48% | 391B | |
| 106.24x | 6.06x | 25.8x | 2.28% | 369B | |
| 23.19x | 5.95x | 14.36x | 2.69% | 307B | |
| 24.47x | 4.89x | 13.59x | 1.77% | 290B | |
| 29.55x | 7.53x | 13.48x | 2.16% | 252B | |
| -41.18x | 7.46x | 46.76x | 1.93% | 212B | |
| Average | 31.35x | 7.39x | 21.65x | 2.01% | 426.2B | |
| Weighted average by Cap. | 37.16x | 8.83x | 22.81x | 1.69% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IRLAB A Stock
- Valuation IRLAB Therapeutics AB
Select your edition
All financial news and data tailored to specific country editions
